Published in
American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 6(66), 2022
DOI: 10.1128/aac.02075-21
Links
Tools
Distribution of Common and Rare Genetic Markers of Second-Line-Injectable-Drug Resistance in Mycobacterium tuberculosis Revealed by a Genome-Wide Association Study
,
Calvin Kim,
Sarah M. Ramirez-Busby,
Samuel J. Modlin ,
Mikael Mansjö,
Jim Werngren,
Leen Rigouts,
Sven E. Hoffner,
Faramarz Valafar
Full text: Download
Abstract
Point mutations in the rrs gene and the eis promoter are known to confer resistance to the second-line injectable drugs (SLIDs) amikacin (AMK), capreomycin (CAP), and kanamycin (KAN). While mutations in these canonical genes confer the majority of SLID resistance, alternative mechanisms of resistance are not uncommon and threaten effective treatment decisions when using conventional molecular diagnostics.